1. Singapore Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Cordlife Group Limited

Cordlife Group Limited

CLIFF
Cordlife Group LimitedUS flagOther OTC
0.10
USD
- -
- -
26.25MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.15
0.19
0.22
0.23
0.23
0.27
0.24
0.23
0.22
0.22
0.22
0.11
0.15
0.15
Basic EPS, GAAP
0.06
0.12
0.12
0.05
-0.01
0.01
0.03
0.03
0.02
0.02
0.01
-0.07
-0.05
-0.05
Free Cash Flow per Basic Share
0.03
0.01
-0.02
-0.04
0.01
0.03
0.04
0.06
0.03
0.02
0.03
-0.06
-0.01
-0.01
Dividend per Share
0.03
0.02
0.02
0.14
- -
- -
- -
0.01
0.01
0.01
- -
- -
- -
- -
Book Value per Share
0.34
0.58
0.67
0.58
0.59
0.21
0.62
0.63
0.65
0.65
0.66
0.59
0.54
0.53
Tangible Book Value per Share
0.33
0.54
0.61
0.46
0.45
0.31
0.38
0.4
0.41
0.41
0.42
0.35
0.3
0.29
Basic Weighted Avg Shares
233
257
260
259
259
253
254
254
255
256
256
256
256
256
Sales/Revenue/Turnover
35
49
58
60
60
68
62
59
57
55
56
28
39
38
Operating Margin (%)
21.13
17.67
9.51
1.76
-0.33
4.73
-5.42
7.58
7.06
2.22
-0.73
-87.18
-38.19
-36.68
Depreciation Expense
1
2
2
3
3
3
4
4
4
4
4
4
4
4
Net Income, GAAP
13
31
32
12
-3
3
6
7
6
5
4
-19
-13
-13
Effective Tax Rate (%)
7.38
4.63
3.44
5.7
- -
26.4
20.47
13.26
12.47
11.21
16.25
- -
- -
- -
Profit Margin (%)
38.86
62.18
56.37
20.68
-4.29
4.79
10.51
11.1
10.83
8.86
6.32
-67.11
-32.53
-33.31
Working Capital
10
42
30
131
67
82
57
77
76
87
80
66
56
48
LT Debt
6
8
125
76
7
4
5
6
1
1
2
1
1
1
Total Equity
78
141
162
133
130
121
129
133
137
134
136
119
104
102
Return on Invested Capital (%)
8.58
6.94
2.37
0.39
- -
1.79
-2.03
2.86
2.56
0.82
-0.25
- -
- -
- -
Return on Capital (%)
16.78
25.04
16.1
6.48
- -
3.19
6
4.1
3.75
2.98
2.16
- -
- -
- -
Return on Common Equity (%)
17.69
26.8
20.08
7.55
-1.69
3.15
6.11
4.11
3.77
2.95
2.09
-11.63
-8.72
-18.64

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
4
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
256
256
256
Market Capitalization
41
23
23

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
77
85
79
Cash, Cash Equivalents & STI
43
51
45
Accounts Receivable, Net
27
25
25
Inventories
1
1
1
Total Current Liabilities
28
29
31
Payables & Accruals
- -
- -
- -
ST Debt
1
1
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.98%
-4.53%
-11.95%
Free Cash Flow
-25.02%
-92.51%
-90.94%
Net Income, GAAP
-102.85%
-143.46%
-32.36%
Sales/Revenue/Turnover
-1.21%
-3.21%
39.54%
Total Cash Common Dividend
- -
- -
-2.7%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
10
8
- -
28
2025
10
10
10
9
39
2026
9
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
-0.02
- -
-0.07
2025
-0.01
- -
-0.01
-0.02
-0.05
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Xiaoling Chen
Full Time Employees
596
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
A’Posh Bizhub Singapore Singapore 768160
IPO Date
Feb 15, 2013
Website
cordlife.com
Similar Companies
Thermo Fisher Scientific Inc. (TN8.DE)
AccuStem Sciences Limited (ACMSY)
DIVA Laboratories, Ltd. (4153.TWO)
ANGLE plc (AGL.L)
PT Prodia Widyahusada Tbk (PRDA.JK)
Medivolve Inc. (MEDV.NE)
Business
Cordlife Group Limited operates as an investment holding company, primarily providing specialized healthcare services focused on maternal and child health across Asia. The company maintains a significant operational footprint in Singapore, Hong Kong, India, Indonesia, Malaysia, and the Philippines, further extending its reach into markets like Thailand, Myanmar, and Vietnam through various affiliations. Its business structure encompasses two main divisions: Banking and Diagnostics. The Banking segment delivers comprehensive services for the processing and cryogenic storage of stem cells derived from cord blood, cord lining, cord tissue, and even placenta, alongside corneal lenticule banking. Meanwhile, the Diagnostics segment offers a wide array of genetic screening and testing solutions, including non-invasive prenatal evaluations, newborn metabolic and vision screenings, and advanced genetic analyses for talent and health predispositions. It also provides preimplantation genetic screening and endometrial receptivity assessments. The company has recently navigated considerable operational scrutiny, including a notice of intent from the Singapore Ministry of Health in September 2025 for a one-year suspension of its cord blood banking services, citing continued non-compliance with regulatory standards in critical operational aspects following earlier service resumptions. Cordlife Group Limited was established in 2001 and is based in Singapore.